Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
Alastair J. King(Charles River Laboratories (Netherlands)), Sylvie Laquerre(Johnson & Johnson (United States))
Cited by 216
Related Papers
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition
|Clinical Cancer Research|2011|600
Characterization of <i>In Vivo</i> Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance
|Molecular Cancer Therapeutics|2017|31